Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: Focus on aflibercept

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1175-1186

  Stewart, Michael W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aflibercept; Age related macular degeneration; Bevacizumab, VEGF trap; Choroidal neovascularization; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PLACEBO; RANIBIZUMAB; VASCULOTROPIN;

ARTICLE; CORNEA NEOVASCULARIZATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; SALVAGE THERAPY; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

EID: 84930473104     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S33372     Document Type: Article

References (116)

1. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640-1642.
2. Macular Photocoagulation Study Group. Argon Laser photocoagulation for neovascular maculopathy. Arch Ophthalmol. 1986;104:694-701.
3. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients with Age-Related Macular Degeneration. Arch Ophthalmol. 2002;120:1443-1454.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;334:1432-1444.
6. Martin DF, Maguire MG, Ying G-S. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
7. http://investor.regeneron.com/releasedetail.cfm?ReleaseID= 532099. Accessed March 19, 2012.
8. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000-2010. Am J Ophthalmol. 2012;153(2):209-213. e2.
9. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109-1114.
10. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol. 1994;112:500-509.
11. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993;115:786-791.
12. Bermig J, Tylla H, Jochmann C, et al. Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2002;240:169-175.
13. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967;63(Suppl 1):S1-S139.
14. Green WR, Enger C. Age-related macular degeneration histopathologic studies: the 1992Lorenz E. Zimmerman Lecture. Ophthalmology. 1993:100:1519-1535.
15. Green WR. Histopathology of age-related macular degeneration. Mol Vis. 1999;5:27-36.
16. Arjamaa O, Nikinmaa M, Salminen A, Kaarniranta K. Regulatory role of HIF-1α in the pathogenesis of age-related macular degeneration (AMD). Ageing Res Rev. 2009;8:349-358.
17. Dunaief JL, Dentchev T, Ying G, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol. 2002;120:1435-1442.
18. Stefansson E, Geirsdóttir A, Sigurdsson H. Metabolic physiology in age related macular degeneration. Prog Retin Eye Res. 2011;30:72-80.
19. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32:375-413.
20. Loane E, Nolan JM, O'Donovan O, et al. Transport and retinal capture of lutein and zeaxanthin with reference to age-related macular degeneration. Surv Ophthalmol. 2008;53:68-71.
21. Tserentsoodol N, Sztein J, Campos M, et al. Uptake of cholesterol by the retina occurs primarily via a low density lipoprotein receptor-mediated process. Mol Vis. 2006;12:1306-1318.
22. Barnstable, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res. 2004;23:561-577.
23. Kim PK, Hailey DW, Mullen RT, Lippincott-Schwartz J. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Nat Acad Sci USA. 2008;105:20567-20574.
24. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85:845-881.
25. Algvere PV, Seregard S. Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand. 2002;80:136-143.
26. Delori FC, Goger DG, Dorey CK. Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest Ophthalmol Vis Sci. 2001;42:1855-1866.
27. Sparrow JR, Cai B, Fishkin N, et al. A2E, a fluorophore of RPE lipofuscin: can it cause RPE degeneration? Adv Exp Med Biol. 2003;533:205-211.
28. Warburton S, Southwick K, Hardman RM, et al. Examining the proteins of functional retinal lipofuscin using proteomic analysis as a guide for understanding its origin. Mol Vis. 2005;11:1122-1134.
29. Bindewald A, Bird AC, Dandekar SS, et al. Classification of fundus autofluorescence patterns in early age-related macular disease. Invest Ophthalmol Vis Sci. 2005;46:3309-3314.
30. Holz FG, Bindewald-Wittich A, Fleckenstein M, and FAM-Study Group. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol. 2007;143:463-472.
31. Ruberti JW, Curcio CA, Millican CL, et al. Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch's membrane. Invest Ophthalmol Vis Sci. 2003;44:1753-1759.
32. Huang JD, Presley JB, Chimento MF, et al. Age-related changes in human macular Bruch's membrane as seen by quick-freeze/deep-etch. Exp Eye Res. 2007;85:202-218.
33. Holz FG, Sheraidah G, Pauleikhoff D, et al. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol. 1994;112:402-406.
34. Nordgaard CL, Karunadharma PP, Feng X, Olsen TW, Ferrington DA. Mitochondrial proteomics of the retinal pigment epithelium at progressive stages of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:2848-2855.
35. Hartl FU. Molecular chaperones in cellular protein folding. Nature. 1996;381:571-579.
36. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 2002;295:1852-1858.
37. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000;10:524-530.
38. Wojcik C. Regulation of apoptosis by the ubiquitin and proteosome pathway. J Cell Mol Med. 2002;6:25-48.
39. Kaarniranata K, Salminen A, Eskelinen E, Kopitz J. Heat shock proteins as gatekeepers of proteolytic pathways-implications for age-related macular degeneration (AMD). Ageing Res Rev. 2009;8:128-139.
40. Wassell J, Davies S, Bardsley W, Boulton M. The photoreactivity of the retinal age pigment lipofuscin. J Biol Chem. 1999;274:23828-23832.
41. Holz F, Schutt F, Kopitz J, et al. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci. 1999;40:737-743.
42. Javitt NB, Javitt JC. The retinal oxysterol pathway: a unifying hypothesis for the cause of age-related macular degeneration. Curr Opin Ophthalmol. 2009;20:151-157.
43. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99:14682-14687.
44. Howes KA, Liu Y, Dunaief JL, et al. Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45:3714-3720.
45. Oskolkova OV, Afonyushkin T, Leitner A, et al. ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response. Blood. 2008;112:330-339.
46. Elner SG, Petty HR, Elner VM, et al. TLR4mediates human retinal pigment epithelial endotoxin binding and cytokine expression. Invest Ophthalmol Vis Sci. 2005;46:4627-4633.
47. Ebihara N, Chen L, Tokura T, Ushio H, Iwatsu M, Murakami A. Distinct functions between toll-like receptors 3 and 9in retinal pigment epithelial cells. Ophthalmic Res. 2007;39:155-163.
48. Kumar MV, Nagineni CN, Chin MS, Hooks JJ, Detrick B. Innate immunity in the retina: toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol. 2004;153:7-15.
49. Kindzelskii AL, Elner VM, Elner SG, Yang D, Hughes BA, Petty HR. Toll-like receptor 4 (TLR4) of retinal pigment epithelial cells participates in trans-membrane signaling in response to photoreceptor outer segments. J Gen Physiol. 2004;124:139-149.
50. Paimela T, Ryhänen T, Mannermaa E, et al. The effect of 17β-estradiol on IL-6secretion and NF-kB DNA-binding activity in human retinal pigment epithelial cells. Immunol Lett. 2007;110;139-144.
51. Holtkamp GM, Kijlstra A, Peek R, de Vos AF. Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res. 2001;20:29-48.
52. Yang D, Elner SG, Bian Z, et al. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH in cultured RPE cells. Exp Eye Res. 2007;85:462-472.
53. Salminen A, Kauppinen A, Hyttinen JM, Totopainen E, Kaarniranta K. Endoplasmic reticulum stress in age-related macular degeneration: trigger for neovascularization. Mol Med. 2010;16:535-542.
54. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
55. Penfold PL, Provis JM, Furby JH, Gatenby PA, Billson FA. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1990;228:270-274.
56. Gurne DH, Tso MO, Edward DP, Ripps H. Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology. 1991;98:602-607.
57. Killingsworth MC, Sarks JP, Sarks SH. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye. 1990;4:613-621.
58. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891-1898.
59. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393-403.
60. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994;35:3178-3188.
61. Soubrane G, Cohen SY, Delayre T, et al. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr Eye Res. 1994;13:183-195.
62. Kimura H, Sakamoto T, Hinton DR, et al. A new model of subretinal neovascularization in the rabbit. Invest Ophthalmol Vis Sci. 1995;36:2110-2119.
63. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641-1646.
64. Bouck N. PEDF anti-angiogenic guardian of ocular function. Trends Mol Med. 2002;8:330-334.
65. Duh EJ, Yang HS, Suzuma I, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci. 2002;43:821-829.
66. Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2002;43:2428-2434.
67. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
68. Ogata N, Nishikawa M, Nishimura T, et al. Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Am J Ophthalmol. 2002;133:851-852.
69. Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol. 2001;189:323-333.
70. Renno RZ, Youssri AI, Michaud N, et al. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:1573-1580.
71. Yancopoulos GD, Davis S, Gale NW, et al. vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
72. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6:460-463.
73. Oh H, Takagi H, Suzuma K, et al. Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2in bovine microvascular endothelial cells. J Biol Chem. 1999;274:15732-15739.
74. Green WR, Enger C. Age-related macular degeneration histopathologic studies: the 1992Lorenz E. Zimmerman Lecture. Retina. 2005;25:1519-1535.
75. Green WR, Key SN 3rd. Senile macular degeneration: a histopathologic study. 2005;25:180-250.
76. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293.
77. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1992;114:464-472.
78. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393-403.
79. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
80. Lopez PF, Sippy BD, Lambert HM, et al. Trans-differentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
81. Baffi J, Byrnes G, Chan CC, et al. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2000;41:3582-3589.
82. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001;158:1161-1172.
83. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157:135-144.
84. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularization. Br J Ophthalmol. 1996;80:363-366.
85. Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol. 2002;134:220-227.
86. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
87. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
88. Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
89. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992;187:1579-1586.
90. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
91. Blaauwgeers HGT, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation. Am J Pathol. 1999;155:421-428.
92. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13:37-50.
93. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98:495-504.
94. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219-1224.
95. Papapetropoulos A, Garcia-Cardeña G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenesis properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997;100:3131-3139.
96. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of met alloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998;55:29-42.
97. Mott JD, Werb Z. Regulation of matrix biology by matrix met alloproteinases. Curr Opin Cell Biol. 2004;16:558-564.
98. Kim I, Ryan A, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2in normal eyes. Invest Ophthalmol Vis Sci. 1999;40:2115-2121.
99. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028.
100. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;DOI 10.1007/s10456-011-9249-6.
101. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. PNAS. 2002;99(17):11392-11398.
102. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Reports. 2011;1:e5.
103. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667-668.
104. Dixon JA, Oliver, Olson JL, Mandava N. VEGF Trap-eye for the treatment of age-related macular degeneration. Expert Opin Investig Drugs. 2009;18(10):1573-1580.
105. Cao J, Zhao L, Li Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF Trap. Invest Ophthalmol Vis Sci. 2010;51(11):6009-6017.
106. Saichin Y, Takahashi K, Lima e Silva R, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:241-248.
107. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050.
108. Oliviera HB, Sakimoto T, Javier JAD, et al. VEGF TrapR1R2suppresses experimental corneal angiogenesis. Eur J Ophthalmol. 2010;20:48-54.
109. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:1522-1532.
110. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116:2141-2148.
111. Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011;118:1089-1097.
112. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011;118:1098-1106.
113. Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity. http://investor.regeneron.com/releasedetail.cfm?ReleaseID=629800. Accessed 4/13/2012.
114. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726-733.
115. A Prescription for Savings: Reducing Drug Costs to Medicare. http://aging.senate.gov/events/hr236pr.pdf. Accessed 4/13/2012.
116. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye). Retina. 2012;32(3):343-457.